作者
David JM McGhee, Pamela L Royle, Paul A Thompson, David E Wright, John P Zajicek, Carl E Counsell
发表日期
2013/12
来源
BMC neurology
卷号
13
页码范围
1-13
出版商
BioMed Central
简介
Background
Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true disease-modifying effects. A systematic review was undertaken to determine what biomarkers for disease progression in Parkinson’s disease (PD) exist.
Methods
MEDLINE and EMBASE (1950–2010) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with idiopathic PD diagnosed by formal criteria or clearly described clinical means were included. We made no restriction on age, disease duration, drug treatment, or study design. We included studies which attempted to draw associations between any tests used to investigate disease progression and any clinical measures of …
学术搜索中的文章
DJM McGhee, PL Royle, PA Thompson, DE Wright… - BMC neurology, 2013